Details of the Drug Pharmacogenomic Perturbation Atlas

Flecainide Drug Info

flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide

Therapeutic Class

Antiarrhythmic Agents

Cross-matching ID

PubChem CID

3356

ChEBI ID

CHEMBL75984

CAS Number

CAS 54143-55-4

TTD Drug ID

D03DAP

VARIDT Drug ID

DR00512

INTEDE Drug ID

DR0700

ACDINA Drug ID

D00278

General Information of Drug (ID: DMSQDLE)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Amoebiasis	1.84	3.51e-2	99/102 (97.06%)	GNAS;COL4A5;GNA11;...
Insulin secretion	1.84	2.63e-2	75/86 (87.21%)	GNAS;SNAP25;GNA11;...
Asthma	1.82	2.37e-2	25/31 (80.65%)	PRG2;FCER1A;HLA-DQA1;...
Pyruvate metabolism	-1.82	1.06e-2	41/47 (87.23%)	ADH1A;ADH5;ADH6;...
Complement and coagulation cascades	-1.84	1.03e-2	76/85 (89.41%)	SERPINA1;F8;CFHR2;...
Ribosome	-1.85	1.18e-2	113/158 (71.52%)	RPL4;RPLP1;RPS27;...
Metabolism of xenobiotics by cytochrome P450	-1.91	6.37e-3	49/77 (63.64%)	GSTA3;CYP1A2;GSTO1;...
Retinol metabolism	-1.95	6.37e-3	41/68 (60.29%)	RDH8;CYP2B6;PNPLA4;...
Cholesterol metabolism	-1.99	4.78e-3	44/50 (88%)	ANGPTL4;VDAC1;APOB;...
Tyrosine metabolism	-2.01	6.37e-3	30/36 (83.33%)	GOT1;TH;AOC2;...
Proteasome	-2.04	6.37e-3	44/46 (95.65%)	PSMB4;PSMB1;PSMD13;...
PPAR signaling pathway	-2.31	0.00e+0	66/74 (89.19%)	PPARD;AQP7;PLTP;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	12uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H